NO20005341L - Behandling av depresjon og farmasöytiske sammensetninger for dette - Google Patents

Behandling av depresjon og farmasöytiske sammensetninger for dette

Info

Publication number
NO20005341L
NO20005341L NO20005341A NO20005341A NO20005341L NO 20005341 L NO20005341 L NO 20005341L NO 20005341 A NO20005341 A NO 20005341A NO 20005341 A NO20005341 A NO 20005341A NO 20005341 L NO20005341 L NO 20005341L
Authority
NO
Norway
Prior art keywords
depression
treatment
pharmaceutical compositions
daily dose
folic acid
Prior art date
Application number
NO20005341A
Other languages
English (en)
Other versions
NO20005341D0 (no
Inventor
Alec James Coppen
Original Assignee
Scarista Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9808840A external-priority patent/GB2336534A/en
Priority claimed from GBGB9815372.9A external-priority patent/GB9815372D0/en
Application filed by Scarista Ltd filed Critical Scarista Ltd
Publication of NO20005341D0 publication Critical patent/NO20005341D0/no
Publication of NO20005341L publication Critical patent/NO20005341L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Det er funnet at behandlingen av depresjon ved bruk av kjente SRPer og NRTer kan forbedres ved administrering sammen med disse av folsyre eller en forløper derav som gir folat hos en pasient.Den daglige dose av NRI eller SRIér som foreskrevet for behandling av depresjon på vanlig måte.Den daglige dose folsyreforløperen bør være slik at det gir en folatdosering på 300-5000 mikrog/dag.
NO20005341A 1998-04-24 2000-10-23 Behandling av depresjon og farmasöytiske sammensetninger for dette NO20005341L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9808840A GB2336534A (en) 1998-04-24 1998-04-24 Anti-depressant - Folic Acid Combination
GBGB9815372.9A GB9815372D0 (en) 1998-07-15 1998-07-15 Treatment of depression and pharmaceutical preparations therefor
PCT/GB1999/001268 WO1999055338A1 (en) 1998-04-24 1999-04-23 Treatment of depression and pharmaceutical preparations therefor

Publications (2)

Publication Number Publication Date
NO20005341D0 NO20005341D0 (no) 2000-10-23
NO20005341L true NO20005341L (no) 2000-12-08

Family

ID=26313533

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20005341A NO20005341L (no) 1998-04-24 2000-10-23 Behandling av depresjon og farmasöytiske sammensetninger for dette

Country Status (14)

Country Link
EP (1) EP1071425B1 (no)
JP (1) JP2002512965A (no)
KR (1) KR100398791B1 (no)
AT (1) ATE369135T1 (no)
AU (1) AU765173B2 (no)
CA (1) CA2329665C (no)
DE (1) DE69936773T2 (no)
DK (1) DK1071425T3 (no)
ES (1) ES2292238T3 (no)
NO (1) NO20005341L (no)
NZ (1) NZ508310A (no)
PT (1) PT1071425E (no)
RU (1) RU2222329C2 (no)
WO (1) WO1999055338A1 (no)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX354547B (es) * 2011-11-14 2018-03-09 Alfasigma Spa Ensayos y métodos para seleccionar un regimen de tratamiento para un sujeto con depresión.
RU2717343C1 (ru) * 2019-03-01 2020-03-23 Евгений Владимирович Плотников Средство, обладающее цитопротекторным действием
CN113350375A (zh) * 2021-05-24 2021-09-07 北京斯利安药业有限公司 一种药用组合物及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2072504B (en) * 1980-03-27 1983-10-26 Coppen A J Pharmaceutical compositions
WO1983001199A1 (en) * 1981-10-05 1983-04-14 Alec James Coppen Pharmaceutical compositions
EP0386117B1 (en) * 1987-10-22 1999-01-07 Massachusetts Institute Of Technology Treating premenstrual or late luteal phase syndrome
IT1229517B (it) * 1989-01-31 1991-09-03 Bioresearch Spa Impiego di acido 5-metiltetraidrofolico, di acido 5 formiltetraidrofolico, e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato adatte ad essere impiegate nella terapia dei disordini depressivi e composizioni farmaceutiche relative.
CA2160423A1 (en) * 1994-11-02 1996-05-03 Hemant N. Joshi Salts of nefazodone having improved dissolution rates
EP0714663A3 (en) * 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
GB9617990D0 (en) * 1996-08-29 1996-10-09 Scotia Holdings Plc Treatment of pain
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
UA57107C2 (uk) * 1997-09-23 2003-06-16 Елі Ліллі Енд Компані Спосіб лікування розладу поведінки

Also Published As

Publication number Publication date
PT1071425E (pt) 2007-11-16
EP1071425B1 (en) 2007-08-08
ATE369135T1 (de) 2007-08-15
KR20010072579A (ko) 2001-07-31
AU3620399A (en) 1999-11-16
KR100398791B1 (ko) 2003-09-19
NO20005341D0 (no) 2000-10-23
AU765173B2 (en) 2003-09-11
CA2329665C (en) 2007-09-04
JP2002512965A (ja) 2002-05-08
DE69936773D1 (de) 2007-09-20
EP1071425A1 (en) 2001-01-31
RU2222329C2 (ru) 2004-01-27
CA2329665A1 (en) 1999-11-04
DE69936773T2 (de) 2008-04-30
ES2292238T3 (es) 2008-03-01
WO1999055338A1 (en) 1999-11-04
NZ508310A (en) 2005-03-24
DK1071425T3 (da) 2007-12-27

Similar Documents

Publication Publication Date Title
TW200630123A (en) Oral medicinal product with modified release of at least one active principle in multimicrocapsular form
IL154888A (en) Aqueous Pharmaceutical Gel Preparation Containing At least One Vitamin D or One Vitamin D Analog At least One Corticosteroid
TR200002207T1 (tr) Slekoksib bileşikleri.
HUP0400529A2 (hu) Klórpromazin és pentamidin alkalmazása daganatképződéssel járó rendellenességek kezelésére szolgáló gyógyszerkészítmények előállítására
BG106251A (en) Levodopa (carbidopa) entacapone pharmaceutical preparation
NO20062398L (no) Daglig, oral, kontrollert frigivnings oksycodon-doserings form
MXPA03011538A (es) Composicion medicinal que sustancialmente no causaria dano a la mucosa intestinal.
BRPI0108435B8 (pt) formulação e uso de entecavir de baixa dose
MXPA02002681A (es) Uso de metabolitos de acido alfa-linolenico para el tratamiento o prevencion del cancer.
HK1087336A1 (en) Pharmaceutical composition comprising lumiracoxib
MXPA03008999A (es) Composicion farmaceutica solida que comprende 4-ciano -trifluor-3 -(4-fluorfenilsulfonil) -2-hidroxi-2 -metilpropino -m-toluidida y pvp.
ATE298324T1 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
DE60004797D1 (de) Arzneimittel mit verzögerter wirkstoffabgabe enthaltend isoquercetin und ascorbinsäure
HK1068606A1 (en) Novel aminobenzoephenones
MXPA06000332A (es) Nueva composicion farmaceutica solida que comprende amisulprida.
MXPA05008843A (es) Sistema terapeutico que comprende amoxicilina y acido clavulanico.
NO20005341L (no) Behandling av depresjon og farmasöytiske sammensetninger for dette
TR200401810T4 (tr) Kısırlık tedavisinde fsh'ın kullanılması
ITMI980356A1 (it) Composizioni orali a basso dosaggio di proteine citotossiche
ATE293445T1 (de) Herstellung reiner stereoisomere von tricyclo- (5.2.1.0(2.6) )-dec-9-yl-xanthogenat sowie deren verwendung als arzneimittel
JO2296B1 (en) Substituted pyrolates
HUP9800623A2 (hu) (+)-O-demetil-tramadol felhasználása fájdalomcsillapító hatású orális gyógyszerkészítmények előállítására
ATE493976T1 (de) Bakuchiol enthaltende pharmazeutische zusammensetzung zur behandlung von weiblicher osteoporose
MD1610G2 (ro) Metodă de tratament al stomatitei aftoase recidivante cronice
MD2068G2 (ro) Metodă de tratament al infecţiei cu Herpes simplex

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application